{"pmid":32470485,"title":"Does asthma affect morbidity or severity of Covid-19?","text":["Does asthma affect morbidity or severity of Covid-19?","J Allergy Clin Immunol","Matsumoto, Kenji","Saito, Hirohisa","32470485"],"journal":"J Allergy Clin Immunol","authors":["Matsumoto, Kenji","Saito, Hirohisa"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470485","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jaci.2020.05.017","keywords":["t2 cytokines","angiotensin-converting enzyme 2","asthma","coronavirus disease 2019","interferon"],"topics":["Treatment"],"weight":1,"_version_":1668167109904957441,"score":9.490897,"similar":[{"pmid":32358994,"title":"Asthma and COVID-19: is asthma a risk factor for severe outcomes?","text":["Asthma and COVID-19: is asthma a risk factor for severe outcomes?","When I first read the manuscript that accompanies this editorial, upon its online publication on February 19(th) 2020(1), COVID-19 had already killed 2118 people in China, but only one person in Europe - an 80-year-old tourist from China, who died in France on the 15(th) February. I read the manuscript with grim fascination, as it was clear that SARS-CoV-2 had spread very rapidly in China which already had 74,576 cases and in South Korea which already had 58 cases, and that it was then invading Europe also, as France already had 12 cases, Germany 16, the UK 9, Italy 3, Spain 2 and other countries too.","Allergy","Johnston, Sebastian L","32358994"],"abstract":["When I first read the manuscript that accompanies this editorial, upon its online publication on February 19(th) 2020(1), COVID-19 had already killed 2118 people in China, but only one person in Europe - an 80-year-old tourist from China, who died in France on the 15(th) February. I read the manuscript with grim fascination, as it was clear that SARS-CoV-2 had spread very rapidly in China which already had 74,576 cases and in South Korea which already had 58 cases, and that it was then invading Europe also, as France already had 12 cases, Germany 16, the UK 9, Italy 3, Spain 2 and other countries too."],"journal":"Allergy","authors":["Johnston, Sebastian L"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358994","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/all.14348","keywords":["covid-19","asthma"],"locations":["China","China","France","China","South Korea","France","Germany","GBR","Italy","Spain"],"countries":["Germany","Korea, Republic of","Spain","United Kingdom","China","Italy","France"],"countries_codes":["DEU|Germany","KOR|Korea, Republic of","ESP|Spain","GBR|United Kingdom","CHN|China","ITA|Italy","FRA|France"],"topics":["Treatment","Prevention","Diagnosis"],"weight":1,"_version_":1666138495304859649,"score":65.182686},{"pmid":32468411,"title":"COVID-19 and Asthma: Reflection During the Pandemic.","text":["COVID-19 and Asthma: Reflection During the Pandemic.","Coronavirus disease 2019 (COVID-19) is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and abnormal, overactivated innate immunity and \"cytokine storms\" have been proposed as potential pathological mechanisms for rapid COVID-19 progression. Theoretically, asthmatic patients should have increased susceptibility and severity for SARS-CoV-2 infection due to a deficient antiviral immune response and the tendency for exacerbation elicited by common respiratory viruses. However, existing studies have not shown an expected prevalence of asthmatic individuals among COVID-19 patients. Certain aspects of type 2 immune response, including type 2 cytokines (IL-4, IL-13, etc.) and accumulation of eosinophils, might provide potential protective effects against COVID-19. Furthermore, conventional therapeutics for asthma, including inhaled corticosteroids, allergen immunotherapy (AIT), and anti-IgE monoclonal antibody, might also reduce the risks of asthmatics suffering infection of the virus through alleviating inflammation or enhancing antiviral defense. The interactions between COVID-19 and asthma deserve further attention and clarification.","Clin Rev Allergy Immunol","Liu, Shuang","Zhi, Yuxiang","Ying, Sun","32468411"],"abstract":["Coronavirus disease 2019 (COVID-19) is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and abnormal, overactivated innate immunity and \"cytokine storms\" have been proposed as potential pathological mechanisms for rapid COVID-19 progression. Theoretically, asthmatic patients should have increased susceptibility and severity for SARS-CoV-2 infection due to a deficient antiviral immune response and the tendency for exacerbation elicited by common respiratory viruses. However, existing studies have not shown an expected prevalence of asthmatic individuals among COVID-19 patients. Certain aspects of type 2 immune response, including type 2 cytokines (IL-4, IL-13, etc.) and accumulation of eosinophils, might provide potential protective effects against COVID-19. Furthermore, conventional therapeutics for asthma, including inhaled corticosteroids, allergen immunotherapy (AIT), and anti-IgE monoclonal antibody, might also reduce the risks of asthmatics suffering infection of the virus through alleviating inflammation or enhancing antiviral defense. The interactions between COVID-19 and asthma deserve further attention and clarification."],"journal":"Clin Rev Allergy Immunol","authors":["Liu, Shuang","Zhi, Yuxiang","Ying, Sun"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468411","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s12016-020-08797-3","keywords":["allergic diseases","asthma","covid-19","sars-cov-2","type 2 immune response"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887254138880,"score":56.20154},{"pmid":32401670,"title":"Treatment of COVID-19 exacerbated asthma: should systemic corticosteroids be used?","text":["Treatment of COVID-19 exacerbated asthma: should systemic corticosteroids be used?","Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is a new rapidly spreading infectious disease. Current guidance from the World Health Organisation (WHO) highlights asthmatics as a high-risk group for severe illness from COVID-19. Viruses are common triggers of asthma exacerbations and the current SARS-CoV-2 pandemic raises several questions regarding the optimum management strategies. Here, we discuss the contentious issue of whether the mainstay therapies systemic corticosteroids should be used in the routine management of COVID-19-associated asthma exacerbations. Recent guidance from the WHO has advised against the use of corticosteroids if COVID-19 is suspected due to concerns that these agents may impair protective innate anti-viral immune responses. This may not be appropriate in the unique case of asthma exacerbation, a syndrome associated with augmented type 2 inflammation, a disease feature that is known to directly inhibit anti-viral immunity. Corticosteroids, through their suppressive effects on type 2 inflammation, are thus likely to restore impaired anti-viral immunity in asthma and, in contrast to non-asthmatic subjects, have beneficial clinical effects in the context of SARS-CoV-2 infection.","Am J Physiol Lung Cell Mol Physiol","Kumar, Kartik","Hinks, Timothy Sc","Singanayagam, Aran","32401670"],"abstract":["Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is a new rapidly spreading infectious disease. Current guidance from the World Health Organisation (WHO) highlights asthmatics as a high-risk group for severe illness from COVID-19. Viruses are common triggers of asthma exacerbations and the current SARS-CoV-2 pandemic raises several questions regarding the optimum management strategies. Here, we discuss the contentious issue of whether the mainstay therapies systemic corticosteroids should be used in the routine management of COVID-19-associated asthma exacerbations. Recent guidance from the WHO has advised against the use of corticosteroids if COVID-19 is suspected due to concerns that these agents may impair protective innate anti-viral immune responses. This may not be appropriate in the unique case of asthma exacerbation, a syndrome associated with augmented type 2 inflammation, a disease feature that is known to directly inhibit anti-viral immunity. Corticosteroids, through their suppressive effects on type 2 inflammation, are thus likely to restore impaired anti-viral immunity in asthma and, in contrast to non-asthmatic subjects, have beneficial clinical effects in the context of SARS-CoV-2 infection."],"journal":"Am J Physiol Lung Cell Mol Physiol","authors":["Kumar, Kartik","Hinks, Timothy Sc","Singanayagam, Aran"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32401670","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1152/ajplung.00144.2020","keywords":["asthma","covid-19","corticosteroid","exacerbation"],"topics":["Treatment"],"weight":1,"_version_":1666865855080693760,"score":53.5473},{"pmid":32437628,"title":"COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?","text":["COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?","Am J Respir Crit Care Med","Maes, Tania","Bracke, Ken","Brusselle, Guy G","32437628"],"journal":"Am J Respir Crit Care Med","authors":["Maes, Tania","Bracke, Ken","Brusselle, Guy G"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437628","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1164/rccm.202005-1651ED","keywords":["covid-19","sars-cov-2","asthma","inhaled corticosteroids"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393781112832,"score":51.413097},{"pmid":32418233,"title":"Allergy and asthma in children and adolescents during the COVID outbreak: what we know and how we could prevent allergy and asthma flares?","text":["Allergy and asthma in children and adolescents during the COVID outbreak: what we know and how we could prevent allergy and asthma flares?","Coronavirus disease 2019 (COVID-19) pandemic is affecting people at any age with a more severe course in patients with chronic diseases or comorbidities, males and elderly patients. The Center for Disease Control and Prevention (CDC) initially proposed that patients with chronic lung diseases, including moderate-severe asthma, and allergy may have a higher risk of developing severe COVID-19 than otherwise healthy people (https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/asthma.html).","Allergy","Licari, Amelia","Votto, Martina","Brambilla, Ilaria","Castagnoli, Riccardo","Piccotti, Emanuela","Olcese, Roberta","Tosca, Maria Angela","Ciprandi, Giorgio","Luigi Marseglia, Gian","32418233"],"abstract":["Coronavirus disease 2019 (COVID-19) pandemic is affecting people at any age with a more severe course in patients with chronic diseases or comorbidities, males and elderly patients. The Center for Disease Control and Prevention (CDC) initially proposed that patients with chronic lung diseases, including moderate-severe asthma, and allergy may have a higher risk of developing severe COVID-19 than otherwise healthy people (https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/asthma.html)."],"journal":"Allergy","authors":["Licari, Amelia","Votto, Martina","Brambilla, Ilaria","Castagnoli, Riccardo","Piccotti, Emanuela","Olcese, Roberta","Tosca, Maria Angela","Ciprandi, Giorgio","Luigi Marseglia, Gian"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32418233","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/all.14369","keywords":["allergy","covid-19","sars-cov2 infection","adolescents","asthma","children"],"topics":["Prevention"],"weight":1,"_version_":1667058206763909121,"score":50.535408}]}